Loading…
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | $-255M | $-313M | $-179M | -61.5% | -25.1% | -42.8% |
| 2024 | $227M | $-484M | $-547M | $-382M | -76.4% | -9.7% | -38.7% |
| 2023 | $251M | $-822M | $-893M | $-336M | -81.4% | -47.4% | -57.6% |
| 2022 | $478M | $-2.1B | $-2.1B | $-304M | -121.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 477.71 | 251.46 | 227.04 | 170.16 |
| Operating Revenue | - | 477.71 | 251.46 | 227.04 | 170.16 |
| Cost Of Revenue | - | 204.22 | 54 | 44.55 | 46.97 |
| Gross Profit | - | 273.49 | 197.45 | 182.50 | 123.18 |
| Operating Expense | - | 2,482.44 | 965.65 | 670.22 | 427.06 |
| Research And Development | - | 1,052.64 | 580.62 | 424.06 | 243.77 |
| Selling General And Administration | - | 1,429.80 | 385.02 | 246.16 | 183.29 |
| Total Expenses | - | 2,686.66 | 1,019.65 | 714.77 | 474.04 |
| Operating Income | - | -2,208.95 | -768.20 | -487.73 | -303.88 |
| Total Operating Income As Reported | - | -2,208.95 | -864.41 | -559.76 | -315.28 |
| EBITDA | - | -2,078.74 | -822.34 | -484.39 | -254.61 |
| Normalized EBITDA | - | -2,182.26 | -633.97 | -382.22 | -226.80 |
| EBIT | - | -2,121.29 | -892.85 | -547.41 | -313.60 |
| Interest Income | - | 20.26 | 57.22 | 38.61 | 22.62 |
| Interest Expense | - | 0.11 | 0.09 | 0.09 | 0 |
| Net Interest Income | - | 20.16 | 57.12 | 38.52 | 22.62 |
| Other Non Operating Income Expenses | - | 7.63 | 9.14 | 3.87 | -4.53 |
| Other Income Expense | - | 67.40 | -181.87 | -98.30 | -32.34 |
| Interest Income Non Operating | - | 20.26 | 57.22 | 38.61 | 22.62 |
| Interest Expense Non Operating | - | 0.11 | 0.09 | 0.09 | 0 |
| Net Non Operating Interest Income Expense | - | 20.16 | 57.12 | 38.52 | 22.62 |
| Pretax Income | - | -2,121.40 | -892.94 | -547.51 | -313.60 |
| Tax Provision | - | -15.03 | -0.07 | -0.48 | -0.84 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.73 | -0.01 | -0.10 | -0.08 |
| Net Income Continuous Operations | - | -2,106.37 | -892.87 | -547.03 | -312.76 |
| Net Income From Continuing And Discontinued Operation | - | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Net Income From Continuing Operation Net Minority Interest | - | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Net Income | - | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Net Income Common Stockholders | - | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Net Income Including Noncontrolling Interests | - | -2,106.37 | -892.87 | -547.03 | -312.76 |
| Normalized Income | - | -2,207.72 | -704.51 | -444.96 | -285.04 |
| Diluted NI Availto Com Stockholders | - | -2,104.93 | -892.87 | -547.03 | -312.76 |
| Basic Average Shares | - | 41.98 | 48.61 | 51.89 | 55.46 |
| Diluted Average Shares | - | 42 | 48.61 | 51.89 | 55.46 |
| Reconciled Depreciation | - | 42.55 | 70.51 | 63.02 | 58.99 |
| Reconciled Cost Of Revenue | - | 204.22 | 54 | 44.55 | 46.97 |
| Total Unusual Items | - | 103.52 | -188.37 | -102.17 | -27.81 |
| Total Unusual Items Excluding Goodwill | - | 103.52 | -188.37 | -102.17 | -27.81 |
| Minority Interests | 6.60 | 1.44 | 0 | 0 | - |
| Special Income Charges | - | 31.89 | -138.71 | -79.04 | -11.40 |
| Gain On Sale Of Business | - | 31.89 | -42.50 | -7.01 | 0 |
| Other Special Charges | -23.83 | - | - | - | - |
| Impairment Of Capital Assets | - | 0 | 96.21 | 47.86 | 0 |
| Restructuring And Mergern Acquisition | - | 0 | 0 | 24.17 | 11.40 |
| Gain On Sale Of Security | - | 71.64 | -49.66 | -23.13 | -16.41 |
| General And Administrative Expense | - | 1,429.80 | 385.02 | 246.16 | 183.29 |
| Other Gand A | - | 1,429.80 | 385.02 | 246.16 | 183.29 |
| Otherunder Preferred Stock Dividend | 58.62 | 3.14 | 0 | - | - |
| Earnings From Equity Interest | - | -43.76 | -2.64 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.this co. | DNA | $591M | -1.89 | 1.16 | -61.5% | -3.39 |
| Beta Bionics, Inc. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Gyre Therapeutics, Inc. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| Phreesia, Inc. | PHR | $599M | 259.74 | 1.78 | 0.7% | 21.30 |
| Bioventus Inc. | BVS | $589M |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 25.93 |
| 3.20 |
| 12.3% |
| 8.39 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Rigel Pharmaceuticals, Inc. | RIGL | $560M | 1.52 | 1.43 | 93.8% | 4.35 |
| Peer Median | - | 18.76 | 2.36 | 6.7% | 6.83 | |